Latest Information Update: 27 Jul 2001
At a glance
- Originator Shire Pharmaceuticals Group
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 27 Jul 2001 Discontinued-I for Epilepsy in USA (Unknown route)
- 07 Sep 2000 Phase-I clinical trials for Epilepsy in USA (Unknown route)
- 01 Sep 1999 New profile